Minerva (Cyproterone Acetate, Ethinylestradiol)

Cyproterone acetate and ethinylestradiol, the active ingredients in Minerva, are a combined oral contraceptive presented as a 2 mg/35 µg tablet for oral use. It provides hormonal contraception and is also employed to treat acne, hirsutism, and other androgen‑dependent skin disorders in women of reproductive age.

GNH USA supplies Minerva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and offers reliable global distribution.

Minerva, a combined oral contraceptive, is indicated for conditions that involve hormonal regulation and androgen‑dependent skin disorders.

- Contraception: Prevents pregnancy by suppressing ovulation in women of reproductive age. - Acne vulgaris: Reduces inflammatory acne lesions by decreasing androgen activity in the skin. - Hirsutism: Decreases excess facial and body hair growth through anti‑androgen effects. - Androgen‑dependent skin disorders: Improves symptoms such as seborrhoea by lowering androgen stimulation.

Minerva may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea: Mild to moderate stomach upset, especially during the first cycles. - Headache: Transient tension‑type headaches reported by many users. - Breast tenderness: Sensitivity or swelling of breast tissue. - Spotting or irregular bleeding: Breakthrough bleeding, particularly in the initial months.

Serious or Rare Side Effects: - Venous thromboembolism: Deep vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Severe allergic reaction: Anaphylaxis or angioedema, presenting with rash, swelling, and breathing difficulty.

Before prescribing Minerva, clinicians should consider several safety precautions to minimize risk.

- Pregnancy contraindication: Product is classified as pregnancy category X and must not be used during pregnancy. - Smoking and cardiovascular risk: Avoid in women over 35 who smoke due to increased thrombotic risk. - Liver disease: Use with caution in patients with hepatic impairment. - Migraine with aura: Contraindicated because of heightened stroke risk. - Drug interactions: Review concomitant medications for CYP3A4 inducers or anticoagulants. - Store at ambient temperature: Keep tablets below 25 °C in the original pack, protected from moisture.

Minerva can interact with several medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): May reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): Combined use can increase bleeding risk. - Additional estrogen‑containing products: May amplify estrogen‑related adverse events.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors: May increase risk of mood changes. - Antihypertensives: Hormonal effects can alter blood pressure control. - Certain antiretrovirals (e.g., protease inhibitors): May affect hormone levels and efficacy.